|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
NEOPLASIA
From the Department of Haematology, Faculty of
Medicine, Imperial College of Science, Technology and Medicine, London,
United Kingdom and III. Medizinische Klinik, Universitätsklinikum
Mannheim, Fakultät für Klinische Medizin Mannheim der
Universität Heidelberg, Germany.
Constitutive activation of the BCR-ABL tyrosine kinase
is fundamental to the pathogenesis of chronic myeloid leukemia (CML). STI571 inhibits this activity and modulates the transcription of
several genes. It was shown by differential display that the suppressor
of cytokine signaling-2 (SOCS-2) gene was down-regulated by
STI571 treatment in 14 of 16 BCR-ABL-positive cell lines
and in 2 BCR-ABL-transfected murine lines, but not in
BCR-ABL-negative counterparts. The effect was maximal at 2 hours and persisted for at least 24 hours after exposure to 1 µM
STI571, whereas SOCS-1 and SOCS-3 expression
were unaffected. Baseline levels of SOCS-2 were
significantly higher in BCR-ABL-positive as compared with BCR-ABL-negative cell lines. It was similar in leukocytes
and CD34+ cells from healthy persons (n = 44) and
patients with CML in chronic phase (CP; n = 60) but significantly
increased in patients with CML in blast crisis (BC; n = 20)
(P < .0001). Mononuclear cells (MNCs) from 3 of 4 patients with CML in BC showed a 2-fold to 12-fold down-regulation of
SOCS-2 levels on in vitro exposure to STI571; moreover, a
2-fold to 11-fold decrease in SOCS-2 was observed in MNCs
from 7 of 8 patients with CML in BC who responded to treatment with
STI571. Refractoriness to STI571 or relapse after initial response was
accompanied by augmentation of SOCS-2 expression. Ectopic
overexpression of SOCS-2 in 32Dp210 cells slowed growth,
inhibited clonogenicity, and increased their motility and sensitivity
to STI571. Overall, the results suggest that SOCS-2 is a
component of a negative feedback mechanism; it is induced by Bcr-Abl
but cannot reverse its overall growth-promoting effects in blastic transformation.
(Blood. 2002;99:1766-1775) Chronic myeloid leukemia (CML) is a neoplastic
disease of the hematopoietic stem cell that evolves in 3 clinical
stages: chronic phase (CP), accelerated phase (AP), and blast crisis
(BC). It is characterized by a t(9;22)(q34;q11) reciprocal
translocation which gives rise to a 22q-, or Philadelphia (Ph)
chromosome and a derivative 9q+. The translocation results in a
chimeric BCR-ABL gene on the Ph chromosome, which is
expressed as a 210-kd protein.1 This protein exhibits
deregulated tyrosine kinase activity as compared with the normal
p145Abl, and has been shown to be both transforming in
vitro and leukemogenic in vivo. The most compelling evidence that the
p210Bcr-Abl protein is the main causal mechanism of CML is
the demonstration that a CML-like disease can be produced in mice that
received transplants of stem cells transduced with a
BCR-ABL gene.2
It is known that p210Bcr-Abl interferes with a variety of
intracellular signaling pathways, partly via protein-protein
interactions and partly via tyrosine phosphorylation of target
substrates.3 The common endpoint of all these pathways is
the regulation of transcription. The phenotypic expression of the
Bcr-Abl-induced changes is mainly represented by uncontrolled
proliferation, impaired apoptosis, and reduced cell adhesion. The first
2 aspects could explain the clinical observation that during the
chronic phase of CML, expansion of the myeloid compartment apparently
escapes physiologic control while cells still retain the capacity to
differentiate and to function normally. The adhesion defect of CML
progenitors is likely to result from deregulation of the normal
processes that control their cytoskeletal organization, binding to bone marrow stroma and homing properties.4,5
Most of the efforts so far to define possible targets of Bcr-Abl in CML
have led to the identification of proteins which are affected by a
mechanism of posttranslational modification, usually in the form of
constitutive phosphorylation by the Bcr-Abl tyrosine kinase. Little is
known of the actual genes whose transcription is ultimately affected by
this kinase activity. We have previously used the Bcr-Abl tyrosine
kinase inhibitor STI571 to block Bcr-Abl and screen for transcriptional
changes in a lymphoid BC cell line using the technique of differential
display (DD).6 In the present study, we followed the same
approach to compare the gene expression profiles of 2 myeloid BC cell
lines in the presence or absence of STI571. Among the various messages
detected as differentially expressed, one corresponded to the
suppressor of cytokine signaling 2 (SOCS-2) gene.
SOCS-2,7 also known as
SSI-28 and CIS-2,9 is
part of a family of at least 8 SOCS proteins, all characterized by an N-terminal region of great variability, a central SH2 domain and a
C-terminal conserved motif of about 40 amino acids, named the SC-motif,
CH domain, or SOCS box.9,10 Its physiologic role in the
hematopoietic system has not been investigated so far. SOCS-2-deficient mice were reported to suffer from
gigantism due to growth hormone and insulinlike growth factor-1 (IGF-1)
deregulated signaling.11 These mice, however, did not have
any detectable hematologic abnormality when examined at 2 months of
age. In transfected murine fibroblasts and human embryonic kidney
cells, SOCS-2 was shown to bind to the IGF-1
receptor,12 which is known to act as an antiapoptotic
molecule via the phosphoinositol 3 (PI-3) kinase and MAPK pathways.
IGF-1 is also reported to phosphorylate insulin receptor substrate 1 (IRS-1), which interacts with the Ras protein via Grb2 and
SOS.13 Since Ras and PI-3 kinase are both signaling
molecules closely linked to BCR-ABL-mediated malignant transformation,14,15 it is possible that SOCS-2
is involved in the signal transduction cascades in CML cells.
In the present study we show that SOCS-2 is overexpressed in
BCR-ABL-positive blasts and that this overexpression is
abrogated by inhibition of Bcr-Abl. Furthermore, we demonstrate that
SOCS-2 is down-regulated in vivo upon Bcr-Abl tyrosine
kinase inhibition, as shown by an inverse correlation between its level
of expression and the hematologic response of patients with CML treated
with STI571. Ectopic overexpression of SOCS-2 in
BCR-ABL-positive cell lines increased their sensitivity to
STI571 and inhibited their proliferative capacity. The data suggest
that Bcr-Abl-induced SOCS-2 up-regulation is part of a
defective negative feedback loop that is unable to control the
growth-promoting effects of Bcr-Abl in blast crisis.
Cell cultures
Primary cells
Differential display The differential display (DD) assay was performed using the RNAimage kit (GenHunter, Nashville, TN) with minor modifications as previously reported.6 All polymerase chain reactions (PCRs) were set up in duplicate, and only bands differentially expressed in both reactions were further processed. Candidate bands were excised from the gel, the DNA was reamplified by PCR with the original primers, subcloned in the TOPO-TA vector (Invitrogen, Groningen, The Netherlands) following the manufacturer's protocol and used as probes for Northern blotting. Sequence analysis was performed using an ABI377 sequencer (Applied Biosystems, Warrington, United Kingdom) and M13 standard primers; the results were analyzed by the BLAST Search program.17Northern blotting Between 5 µg and 20 µg of total RNA was electrophoresed on a 0.8% agarose gel, blotted onto an uncharged nylon membrane (Hybond N, Amersham, Little Chalfont, United Kingdom) and hybridized with 32P-labeled probes as described.6 A multiple tissue Northern (MTN) blot was purchased from Clontech (Basingstroke, United Kingdom) and hybridized according to the company's instructions. Probes were either isolated from the original DD gel, cloned PCR products, or derived from IMAGE consortium cDNA clones18 (provided by the MRC Human Genome Mapping Project Biological Resources, Hinxton, Cambridge, United Kingdom). A human -actin cDNA probe was used as control for RNA loading (kindly
provided by Dr Philip Mason, Imperial College School of Medicine,
London, United Kingdom). Densitometric analysis of the autoradiographs
was performed using the GelBlotPro software (Ultra-Violet Products,
Cambridge, United Kingdom).
Western blotting Protein lysates were prepared according to Kabarowski et al,19 and Western blots of 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels were immunostained with a SOCS-2 or a c-myc (9E10) antisera (sc-7007 and sc-40; Santa Cruz, Autogen Bioclear, Calne, United Kingdom) using the enhanced chemiluminescence (ECL) system (Amersham). To control for protein loading, the blots were stripped and restained with an actin antibody (A-2066, Sigma).End-point (qualitative) reverse transcriptase-polymerase chain reaction RNA from 105 to 2 × 107 cells was isolated by the protocol of Chomczynski and Sacchi20 or using the RNeasy Kit (Qiagen, Crawley, United Kingdom), and reverse-transcribed as described.21 The following primers were used for single-step PCR amplifications of SOCS-2: exon 1a, sense 5'-GGGTGCACAGCCTCAGGATA; exon 1b, sense 5'-TCGAGGCGATCAGTGGGTGA-3'; exon 3, antisense 5'-TTTCTCTTTGGCTTCATTAACAGTCAT-3'. Separate amplifications of a 342-base pair (bp) fragment of the normal G6PD gene were used as control for cDNA quality as previously published.22Real-time PCR (TaqMan) Primers and probes were designed using the Primer Express 1.0 program (Applied Biosystems). The PCR reactions for SOCS-2 and CIS contained 300 nmol/L of each forward and reverse primer and 150 nmol/L fluorescently labeled probe in a 25 µL reaction. The glyceraldehyde phosphate dehydrogenase (GAPDH) probe was used as a 20× concentrate according to the manufacturer's recommendation. The amplification was performed in an ABI Prism 7700 thermocycler (Applied Biosystems) for 2 minutes at 50°C, 10 minutes at 95°C, followed by 40 cycles of 15 seconds at 95°C and 1 minute at 60°C. Each sample was analyzed for SOCS-2, CIS, and GAPDH expression, and values were expressed as ratios: SOCS-2/GAPDH or CIS/GAPDH. The primer and probe sequences for the amplification of human SOCS-2 were as follows: forward primer, 5'-TGGCGAAGGCCCTGC-3'; reverse primer, 5'-TTTCTCTTTGGCTTCATTAACAGTCAT-3'; probe (on the reverse strand), 5'-TTCCCCAGTACCATCCTGTCTGACCGA-3'. The sequences for the amplification of human CIS were as follows: forward primer, 5'-CCTACCTTCGGGAATCTGGCT-3'; reverse primer, TGGCATCTTCTGCAGGTGTT-3'; probe, 5'-TCCATTACGGCCAGCGAGGCC-3'. The SOCS-2 and CIS probes were labeled at the 5' end with the reporter dye molecule FAM (OSWEL, Southampton, United Kingdom) and the GAPDH probe (Applied Biosystems, cat.no 4310884E) with VIC. Both probes were 3'-labeled with the quencher dye molecule TAMRA. Amplification of genomic DNA was not observed for either gene, and strict precautions were taken to prevent contamination. Ten identical cell suspension aliquots from one control sample were separately lysed, reverse-transcribed, and tested for amplification of both genes. Since the maximum variation between these 10 replicates was 1.97 (mean ± 1 SD), we considered all changes of target gene/GAPDH ratios more than 2 as significant. A semilogarithmic dilution of KYO1 cDNA was included in each plate to be used as a standard for quantification.Flow cytometry and determination of apoptotic cells Samples of 1 × 106 to 2 × 106 cells were permeabilized by fixation in 50% ethanol for 30 minutes on ice, washed in phosphate buffered saline (PBS) and stained with 100 µg/mL propidium iodide (PI). RNase (Boehringer Mannheim, Mannheim, Germany) was added at a concentration of 100 µg/mL. Stained cells were analyzed on a FACscan with the aid of the CellQuest software (Becton Dickinson, Oxford, United Kingdom).Stable transfection The myeloid murine cell line 32Dp210 was cotransfected by electroporation with the myc-tagged pcDNA3 vector carrying the full-length coding sequence of SOCS-2 cDNA (kindly provided by Dr A. Yoshimura, Kurume, Japan) and with pBabe-puro.23 Clones were selected in methylcellulose (H4230, Stem Cell Laboratories, Vancouver, BC, Canada) supplemented with 2 µg/mL puromycin (Sigma), and the expression of SOCS-2 was confirmed by immunoblotting for c-myc and SOCS-2.Clonogenic assays The parental 32Dp210 cells and their transfected counterparts were plated in triplicate in methylcellulose at a concentration of 102/mL to 106/mL with or without 1 µM STI571, and without additional cytokines. The BCR-ABL-negative cell line 32D served as a control for these experiments. The number of colonies was assessed after 7 days incubation at 37°C.Adhesion and migration assays For measurement of adhesion to plastic, cells were plated in quadruplicate in a 96-well flat-bottom tissue culture plate and incubated for 24 hours at 37°C. Due to different proliferative capacities of the cell lines used, a wide range of plating concentrations from 8 × 102 to 2 × 105 cells/100 µL was required. Test wells were then washed twice with PBS to remove the nonadherent cells, the number of remaining cells was assessed by [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphenyl)-2H-tetrazolium, inner salt] (MTS tetrazolium) staining as described elsewhere,24 and expressed as a ratio of adherent/total number of cells. Adhesion to fibronectin was measured by plating 5 × 104 cells/50 µL in a 48-well tissue culture plate (Corning Costar, High Wycombe, Bucks, United Kingdom) coated with the CH-296 fibronectin fragment (RetroNectin; kindly donated by Takara Shuzo, Shiga, Japan).25 The plate was tilted at 80° for 1 hour and then lowered to 30° to 45° for overnight incubation at 37°C. The number of migrating cells was assessed as described.26 Results were normalized against the cells kept in wells under the same conditions with PBS/2% bovine serum albumin (BSA). To further analyze the migratory abilities of transfected versus parental cells, 5 × 104 cells were plated in 100 µL RF-10 in the top chamber of a 5.0 µm Transwell plate (Costar). After 24 hours, the numbers of cells that had migrated to the lower chamber and those that remained in the Transwell were determined by hemocytometer counting of trypan-blue stained cells (modified after Adelsman et al27).Statistical analysis The Mann-Whitney test was used to assess differences between samples.
The human CML cell line KYO1 was treated with 1 µM STI571 for 10 hours. At this time-point, no signs of cell death as determined by
trypan blue exclusion, DNA apoptotic laddering, or propidium iodide
staining were observed (data not shown). DD analysis of cells treated
with STI571 as compared with the nonexposed control culture yielded,
among others, a DNA fragment of approximately 1 kb which appeared
stronger in the nonexposed KYO1 cells. Northern hybridization with the
candidate band confirmed differential expression of a predominant
2.5-kb message (Figure 1A). Sequence of
the DD isolate matched the 3' untranslated region of the human
SOCS-2 gene (GenBank accession no. AF037989).
Alternative splicing of the SOCS-2 gene Northern hybridizations of cell line or primary cell RNA with the probe isolated from the DD gel, cloned PCR products, or IMAGE consortium cDNA clones always showed a predominant 2.5-kb message, whereas an earlier study12 described a major human SOCS-2 mRNA message of approximately 5 kb in various tissues. In order to clarify this discrepancy, we hybridized a multiple-tissue Northern blot with the probe isolated from the DD gel and confirmed our original finding that the major SOCS-2 message is 2.5 kb in length, with a weaker 5-kb band (Figure 1B). A search of the HTGS genomic database with the SOCS-2 cDNA sequence suggested the existence of an alternative exon 1 in addition to that previously published (GenBank accession no. AC012085). PCR amplification of cDNAs derived from 7 BCR-ABL-positive and 4 BCR-ABL-negative cell lines with 5' primers on either exon 1a or exon 1b and a 3' primer on exon 3 showed in both groups 2 distinct transcripts resulting from alternative splicing, with the transcript from exon 1b being the predominant one (Figure 1C). The junctions between the exons were confirmed by sequencing. Cloned PCR products from these amplifications were used as probes for Northern hybridizations and lighted up identical patterns of bands (data not shown).SOCS-2 expression in hematopoietic cell lines In order to determine whether the differential expression of SOCS-2 was restricted to KYO1 cells, we tested 18 CML or Ph-positive ALL cell lines exposed or not exposed to 1 µM STI571 for up to 24 hours by Northern blotting. Sixteen lines showed a 1.5-fold to over 10-fold down-regulation of SOCS-2 levels after exposure to STI571 (Figure 2A). In 12 of these 16 lines, down-regulation was evident at the 10-hour time-point or earlier, whereas in 4 lines (BV173, ALL/MIK, KT1, LAMA84) the effect was better defined after a 24-hour exposure to STI571, possibly because of a slightly lower sensitivity of the latter cell lines to STI571 as compared with KYO1 cells (data not shown). These results were confirmed at the protein level by Western blotting, particularly in the cell lines of lymphoid origin such as BV173, NALM1, TOM1, and MY in which SOCS-2 protein expression was apparently more abundant (data not shown). The remaining 2 BCR-ABL-positive cell lines tested, KCL22 and SD1, both previously shown to be intrinsically resistant to STI57128 either did not show differential expression of SOCS-2 after treatment with STI571 (KCL22), or failed to express SOCS-2 at the level of Northern blot detection (SD1). The 2 STI571-resistant sublines AR230-r and K562-r24 either did not show any (AR230-r) or a significantly lower (K562-r) down-regulation of SOCS-2 when exposed to the inhibitor as assessed by Northern blot and real-time PCR (Figure 2B).
More detailed time-course experiments by RT-PCR, Northern, and Western blotting revealed that SOCS-2 down-regulation in the most responsive BCR-ABL-positive cell lines is first observed after 1 hour of STI571 treatment, peaks at approximately 2 hours and persists for at least 24 to 48 hours (Figure 3A-C). In order to investigate whether the observed pattern of differential
expression after inhibition of the Bcr-Abl tyrosine kinase was limited
to SOCS-2 or represented a general phenomenon in the family
of SOCS genes, we analyzed the expression of CIS,
SOCS-1, and SOCS-3 in KYO1 and other cell lines
treated or not treated with STI571. No difference in the RNA levels of
SOCS-1 and SOCS-3 were detected, whereas
CIS proved to be differentially expressed (Figure 3D).
Comparison of the basal level of SOCS-2 expression in 17 BCR-ABL-positive and 13 BCR-ABL-negative cell
lines confirmed that this was much higher in the former group, with
BCR-ABL-negative cell lines exhibiting either no signals or
only hardly detectable signals (Figure
4A).
Finally, we tested whether ectopic expression of BCR-ABL in human or murine cell lines affected the levels of SOCS-2. The experimental models were represented by the paired MO7e and MO7/p210, the 32D and 32Dp210 cell line,29 and the Baf/tsBCR-ABL thermosensitive cells at the permissive (32°C) and restrictive (39°C) temperatures for activity of the oncoprotein. Baseline expression of SOCS-2 was higher in the BCR-ABL-expressing cell lines (Figure 4B,C). Like the human Ph-positive lines, the murine BCR-ABL-expressing cells showed down-regulation of SOCS-2 after inhibition of the Bcr-Abl tyrosine kinase with STI571, in contrast to 32D and Baf/tsBCR-ABL at 39°C (Figure 4B,D). Addition of IL-3 to the BCR-ABL-positive cell lines resulted in partial (32Dp210) or complete (Baf/tsBCR-ABL) abolition of the STI571 effect, with no difference in the SOCS-2 baseline expression (data not shown). Primary cells SOCS-2 expression in cells from patients with CML and
healthy individuals.
cDNA samples from 44 healthy individuals, 60 patients with CML in CP and 20 patients with CML in BC were analyzed
for SOCS-2 mRNA expression by real-time RT-PCR. The patients
with CML in BC showed a significantly higher level of SOCS-2
expression as compared with healthy individuals or patients with CML in
CP (P < .0001), whereas no significant difference between
the latter 2 groups could be detected (P = .26) (Figure
5A). This was further investigated in
purified CD34+ cells from 5 patients with CML in CP and 8 healthy individuals. The results confirmed that no significant
differences could be detected between these 2 groups
(P = .77). Similarly, comparison of the level of
SOCS-2 mRNA between total WBCs and CD34+ cells
in patients with CML and in healthy individuals showed that the 2 populations of cells have a similar level of SOCS-2 expression, with no significant difference in either of the 2 groups
(P = .35 for patients with CML, P = .20 for
healthy individuals) (data not shown). All in all, the data indicate
that SOCS-2 is overexpressed in patients with CML at the BC
stage, as compared with the CP stage of the disease.
SOCS-2 expression after in vitro exposure to STI571. Next, we examined the levels of SOCS-2 mRNA in MNCs from 4 patients with CML in myeloid BC, and in CD34+ cells from 4 patients with CML in CP and 8 healthy adults, after culture in RF-10 medium for 24 hours and in the presence or absence of 1 µM STI571 for another 24 hours. No significant modulation of SOCS-2 expression after treatment with the kinase inhibitor was detected in either patients with CML in CP or healthy individuals. In contrast, 3 out of 4 patients with CML in BC showed a 2-fold to 12-fold down-regulation of SOCS-2 levels in response to in vitro exposure to STI571 (Figure 5B). Taken together, these results suggest that SOCS-2 overexpression in CML-BC cells can be reduced when the Bcr-Abl tyrosine kinase activity is inhibited. SOCS-2 expression in patients with CML treated with
STI571.
In order to investigate whether SOCS-2 expression in
patients with CML could be also modulated in vivo by STI571, we
examined the levels of SOCS-2 mRNA in MNCs from patients
before and at various intervals during the first 4 to 5 weeks of
treatment with the drug. Pilot analyses by both Northern blot and
real-time RT-PCR in samples from myeloid BC showed a 2-fold to 14-fold
SOCS-2 down-regulation in 4 of 5 patients, starting from day
4 to day 8 of treatment, and persisting for 2 to 4 weeks (Figure
6). In the fifth patient, the levels of
SOCS-2 decreased 2.5-fold within the first week, but
returned to the high pretreatment values at around day 14, when the
patient was reported to be suffering from nausea and severe vomiting,
suggesting that the intake/absorption of the drug might have been
significantly impaired.
Having confirmed a close linear regression (r2 = 0.97) between the Northern and the real-time RT-PCR assays, we used the latter method to extend the investigation to patients in all stages of the disease. We studied 16 patients with CML in CP refractory or intolerant to interferon alpha (IFN-  ), 9 in AP, 12 in BC, and 3 with
Ph-positive ALL in relapse for up to 16 weeks of treatment with STI571.
Although there was a trend for a higher frequency of patients
exhibiting SOCS-2 down-regulation after treatment in the BC,
AP, and Ph-positive ALL groups as compared with those in the CP cohort,
the difference was not statistically significant (data not shown).
However, taking the clinical course of the patients into account, a
direct correlation was observed between the change in SOCS-2
mRNA expression and the response to treatment as assessed by the
percentage of blasts in the peripheral blood and bone marrow. In 7 out
of 8 patients in BC a reduction of blasts under STI571 treatment was
accompanied by a reduction in SOCS-2 levels; the remaining
patient showed a decrease in the number of blasts, but stable levels of
SOCS-2. In contrast, all 3 patients in BC not responding to
STI571 had persistent or increasing levels of SOCS-2. A
similar phenomenon was observed in the 3 patients with Ph-positive ALL,
in whom a reduction in the number of blasts during treatment with
STI571 was accompanied by decreasing levels of SOCS-2.
Furthermore, when one of these patients relapsed while on STI571, a
6-fold increase in SOCS-2 expression was detected in the
peripheral blood MNCs (Table 1).
SOCS-2 expression upon inhibition of downstream BCR-ABL effectors In order to identify the signal transduction pathways through which STI571 down-regulates SOCS-2 in BCR-ABL-positive cells, we exposed 5 of these lines to a series of signal transduction inhibitors (STIs). The BCR-ABL-negative cell lines HL60 and REH were used as controls for these experiments. A dose-response curve was initially generated for each STI by flow cytometric analysis of PI-stained cells. Triplicate fresh cultures were then treated with the maximum dose of each compound found to induce less than 5% apoptotic death within a maximum 24-hour exposure, and harvested at the appropriate time-points for real-time RT-PCR. In comparison with the BCR-ABL-negative cells, the BCR-ABL-positive lines had on average a significant down-regulation of SOCS-2 after exposure to the PI3 kinase (LY294002) inhibitor (P = .007), but not after treatment with the Ras (manumycin A), MEK (U0126), and Jak2 (AG490) inhibitors. None of the compounds induced SOCS-2 down-regulation in the BCR-ABL-negative cell lines tested (Figure 7). Similar analyses in primary blast cells from 2 patients with CML in myeloid BC showed a marked reduction in SOCS-2 levels after exposure to U0126, but not consistently to the other inhibitors (not shown). Limitation in the number of available cells prevented the establishment of preliminary dose-response curves by fluorescence activated cell sorting (FACS) in these patients, and it is possible that the STI doses used to treat these samples were not optimal.
CIS expression in BCR-ABL-positive and BCR-ABL-negative leukemic cell lines Having shown a differential expression of CIS in KYO1 cells after exposure to STI571, with a time response similar to that observed for SOCS-2 (Figure 8A), we wondered whether the expression pattern of the CIS gene was similar to that of SOCS-2. Because only a minority of BCR-ABL-positive and BCR-ABL-negative cell lines (KYO1, CML-T1, BV173, and NALM1) exhibited CIS signals by Northern blotting, we performed these studies by real-time PCR. The baseline expression in the BCR-ABL-positive cell lines proved to be significantly higher than in the BCR-ABL-negative cells (P = .02) (Figure 8B), confirming a more than 2-fold down-regulation of CIS levels after STI571 exposure in 10 out of 15 BCR-ABL-positive cell lines tested. The remaining 5 cell lines, including 2 (KCL22, SD1) that are resistant to STI571, showed no significant differences in CIS expression levels. Likewise, no STI571-induced CIS modulation was observed in 7 BCR-ABL-negative cell lines studied (Figure 8C). In primary cells, however, we have so far been unable to detect any correlation between the expression pattern of CIS and the stage of disease or the response to STI571 treatment (data not shown).
Ectopic induction of SOCS-2 overexpression A Myc-tagged SOCS-2 cDNA was stably transfected into 32Dp210 cells, clones were selected in semisolid medium, and the overexpression of SOCS-2 was confirmed by Western blotting (Figure 9A). Similar attempts to generate SOCS-2-transfected 32D cells were unsuccessful, as the antibiotic-selected clones did not survive beyond a few passages in liquid culture. The 32Dp210/SOCS-2 cells showed an impaired growth in liquid culture when compared with their parental 32Dp210 counterparts or cells transfected with pcDNA3.1 only. Moreover, 32Dp210/SOCS-2 cells died more rapidly than 32Dp210 upon exposure to 1 µM STI571 (Figure 9B). These findings were confirmed by plating the cells in methylcellulose, where 32Dp210/SOCS-2 cells were significantly less clonogenic than 32D cells transfected with BCR-ABL alone (P = .05), but still showed a higher clonogenicity than 32D cells (P = .05) (Figure 10A). We also observed a small though nonsignificant trend for 32Dp210/SOCS-2 cells to adhere less to plastic than the vector-only transfected control cells. However, 32Dp210/SOCS-2 cells were still more adherent than 32D cells, which are hardly adherent to either plastic or fibronectin at all, suggesting that overexpression of SOCS-2 does not completely counteract the effect of BCR-ABL in this system (Figure 10B). This observation was reinforced by the finding that a significantly higher proportion of 32Dp210/SOCS-2 cells could migrate in both the "tilted dish" assay (Figure 10C) and through a Transwell membrane (Figure 10D) than could the parental 32Dp210 cells (P = .05 in both assays).
In spite of the successful use of STI571 in clinical trials30,31 and of the elucidation of its binding properties to the Abl kinase domain,32 the downstream mechanisms of STI571 action are still poorly defined. When "switching off" the tyrosine kinase activity of Bcr-Abl with STI571 we identified SOCS-2 as a differentially expressed gene. The evidence that SOCS-2 is in fact a downstream target of Bcr-Abl was provided by several observations. Thus, BCR-ABL-positive (CML and Ph-positive ALL) cell lines not only have a significantly higher level of SOCS-2 expression than BCR-ABL-negative leukemia lines, but also show a selective down-regulation of SOCS-2 mRNA and protein upon STI571 treatment. The fact that BCR-ABL-positive lines resistant to STI571 do not exhibit such down-regulation when exposed to the tyrosine kinase inhibitor strengthens the argument. Furthermore, comparisons between BCR-ABL-transfected and parental (BCR-ABL-negative) murine and human cell lines confirmed a marked higher level of SOCS-2 expression in the former, demonstrating that its induction is effected by the leukemic fusion protein. SOCS-2 overexpression is also evident in primary cells from patients with Ph-positive ALL and CML, where it appears to be exclusive to the advanced stages of disease. This was shown by the higher basal levels of SOCS-2 in BC as compared with CP cells, and by both in vitro and in vivo responses to STI571 in blasts from advanced-stage disease only. The reasons for this association are not clear. We found that the levels of SOCS-2 expression in total WBCs and purified CD34+ cells were entirely comparable, indicating that the disparity in SOCS-2 expression between CP and BC is not due to a maturation-dependent variance in SOCS-2 regulation. It could be argued that rather than being induced by Bcr-Abl itself, SOCS-2 overexpression is a response to a secondary mutation that appears only at blastic transformation. This appears as highly unlikely, since no universal abnormality has so far been identified as a cause of BC. Similarly, it is possible that SOCS-2 up-regulation by Bcr-Abl in the advanced phases of CML reflects cooperative activation by the IGF-1 receptor, although there is so far no evidence that this pathway is preferentially activated in BC. Alternatively, SOCS-2 induction may be a dose-dependent event, requiring a certain threshold of Bcr-Abl expression to take place. This possibility seems more plausible, as there is some evidence that BC cells express more Bcr-Abl than CP progenitors.33 The phenomenon is not universal to all SOCS proteins, but rather specific to the most functionally related pair (SOCS-2 and CIS)34 whose protein sequences (accession nos. AAC34745 and BAA92328, respectively) are 39% identical and 52% similar. Yet, these would appear as less likely candidates for involvement in a hematopoietic disorder than, for example, SOCS-1, whose role in some aspects of hematopoiesis is better defined.35-37 Thus, SOCS-2-deficient mice are notoriously abnormal in their endocrine system, suffering from gigantism due to lack of appropriate feedback control of the GH/IGF-I axis.11 Yet, no obvious hematologic abnormality was identified during their early adult life. It is possible however that in the hematopoietic system, inappropriate up-regulation rather than lack of expression is the important pathologic event. At least in leukemic cell lines, the induction of SOCS-2 by Bcr-Abl appears to be mediated via multiple pathways. However, it seems that the PI3 kinase is the main signal transduction molecule involved, whereas Ras, MEK, and Jak2 are affected in some cellular systems but not in others. In contrast, SOCS-2 expression was not inhibited in BCR-ABL-negative cell lines by any of the compounds tested, suggesting that all these cascades may be selectively utilized by Bcr-Abl for the transcriptional regulation of SOCS-2. The few data available on the mechanisms of SOCS-2 induction come again from the GH activation system which largely signals through IGF-I and this, in turn, via the PI-3K and MAPK pathways.12,13 The intermediates required by Bcr-Abl for activation of these kinases in the process of SOCS-2 up-regulation are still unknown. The main and rather intriguing question arising from our observations is obviously that of the possible function of SOCS-2 in the pathogenesis of CML. By definition, the SOCS proteins "suppress" cytokine signaling and provide a safeguard to avoid continuous stimulation of transcription of "important" genes when a receptor is engaged by its cytokine. The fact that Bcr-Abl induces SOCS-2 and CIS expression appears paradoxical as, in this case, the net effect should be the prevention of continuous up-regulation of these proliferation-controlling genes. In reality, however, the opposite phenomenon characterizes BCR-ABL-positive leukemia, where deregulated cell growth is a key phenotypic feature. One possibility is that SOCS-2 may not be a true "suppressor" protein in all cellular systems,12,38,39 and that increased expression of SOCS-2 (as in BCR-ABL-positive cells) restores sensitivity to cytokine signaling by overcoming the inhibitory effect of the other SOCS proteins, particularly SOCS-1.40 An alternative explanation is that in a situation analogous to that triggered by a cytokine-receptor engagement, SOCS-2 is produced in response to constitutive Bcr-Abl signaling but, by mechanisms still not known, accumulates and is not capable of closing the conventional feedback circuit.41 In such scenario, it would appear that SOCS-2 overexpression per se is not causally related to the oncogenic phenotype, but rather its inability to bind to and suppress Bcr-Abl is the contributing factor to the deregulated proliferation of CML. Our data on transduction of SOCS-2 into BCR-ABL-positive cells suggest that the latter possibility is more likely. Thus, ectopic overexpression of the protein was able to only partially overcome the cellular effects of Bcr-Abl, by reducing the rate of proliferation, increasing the sensitivity to STI571-induced cell death, and reverting the motility properties of the transfected cells. The fact that the BCR-ABL "positive" signal is stronger than SOCS-2 and CIS "repressive" influence is also illustrated by the inability of ourselves (data not shown) and others42 to isolate SOCS-2-overexpressing clones from BCR-ABL-negative cells (eg, 32D), which invariably stopped proliferating and died shortly after transfection. A third alternative could in fact be a combination of the first 2, that is, the possibility that within the same cellular system (BCR-ABL-positive leukemias) SOCS-2 may have dual suppressive and stimulating effects, depending on its concentration in the cell.40 Additional studies on the mechanisms of SOCS-2 activation in CML are currently under way to elucidate its possible role in disease progression.
We thank Professor A. Yoshimura (Kurume, Japan) for providing SOCS-2 constructs and Dr Elisabeth Buchdunger (Novartis, Basel, Switzerland) for STI571. We thank the following individuals for cell lines: Dr Fred Falkenburg and B. Nijmeijer (LeidenCML-B; Leiden University Medical Center, Leiden, The Netherlands), Dr S. Mizutani (AR230; National Children's Medical Research Center, Tokyo, Japan), Dr H. Yamauchi (KT1; Ehime University School of Medicine, Japan), Dr K. Inokuchi (MY; Nippon Medical School, Tokyo, Japan), Dr Brian Druker (32D and 32Dp210; Oregon Health Sciences University, Portland, OR), Dr François X. Mahon (Baf/tsBCR-ABL; Université de Bordeaux, France), Dr Felipe Prosper (MO7e and MO7/p210; Clinica Universitaria de Navarra, Pamplona, Spain).
Submitted August 15, 2001; accepted October 25, 2001.
Supported by grants from the Leukaemia Research Fund, London, United Kingdom; and the Dr Mildred Scheel-Stiftung für Krebsforschung, Bonn, Germany.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Junia V. Melo, Department of Haematology, Imperial College of Science, Technology and Medicine, Hammersmith Hospital, Ducane Rd, London W12 0NN United Kingdom; e-mail: j.melo{at}ic.ac.uk.
1.
Melo JV.
The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype.
Blood.
1996;88:2375-2384
2.
Daley GQ, Van Etten RA, Baltimore D.
Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.
Science.
1990;247:824-830 3. Sawyers CL. Signal transduction pathways involved in BCR-ABL transformation. Baillieres Clin Haematol. 1997;10:223-231[Medline] [Order article via Infotrieve]. 4. Salgia R, Li JL, Ewaniuk DS, et al. BCR/ABL induces multiple abnormalities of cytoskeletal function. J Clin Invest. 1997;100:46-57[Medline] [Order article via Infotrieve]. 5. Bhatia R, Wayner EA, McGlave PB, Verfaillie CM. Interferon-alpha restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired beta 1 integrin receptor function. J Clin Invest. 1994;94:384-391.
6.
Deininger MWN, Vieira S, Mendiola R, Schultheis B, Goldman JM, Melo JV.
BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia.
Cancer Res.
2000;60:2049-2055 7. Starr R, Willson TA, Viney EM, et al. A family of cytokine-inducible inhibitors of signalling. Nature. 1997;387:917-921[CrossRef][Medline] [Order article via Infotrieve]. 8. Minamoto S, Ikegame K, Ueno K, et al. Cloning and functional analysis of new members of STAT induced STAT inhibitor (SSI) family: SSI-2 and SSI-3. Biochem Biophys Res Commun. 1997;237:79-83[CrossRef][Medline] [Order article via Infotrieve]. 9. Masuhara M, Sakamoto H, Matsumoto A, et al. Cloning and characterization of novel CIS family genes. Biochem Biophys Res Commun. 1997;239:439-446[CrossRef][Medline] [Order article via Infotrieve].
10.
Hilton DJ, Richardson RT, Alexander WS, et al.
Twenty proteins containing a C-terminal SOCS box form five structural classes.
Proc Natl Acad Sci U S A.
1998;95:114-119 11. Metcalf D, Greenhalgh CJ, Viney E, et al. Gigantism in mice lacking suppressor of cytokine signalling-2. Nature. 2000;405:1069-1073[CrossRef][Medline] [Order article via Infotrieve].
12.
Dey BR, Spence SL, Nissley P, Furlanetto RW.
Interaction of human suppressor of cytokine signaling (SOCS)-2 with the insulin-like growth factor-I receptor.
J Biol Chem.
1998;273:24095-24101
13.
Párrizas M, Saltiel AR, LeRoith D.
Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3'-kinase and mitogen-activated protein kinase pathways.
J Biol Chem.
1997;272:154-161 14. Pendergast AM, Quilliam LA, Cripe LD, et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell. 1993;75:175-185[CrossRef][Medline] [Order article via Infotrieve].
15.
Skorski T, Kanakaraj P, Nieborowska-Skorska M, et al.
Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells.
Blood.
1995;86:726-736 16. Loos JA, Roos D. Changes in the carbohydrate metabolism of mitogenically stimulated human peripheral lymphocytes. 3. Stimulation by tuberculin and allogenic cells. Exp Cell Res. 1973;79:136-142[CrossRef][Medline] [Order article via Infotrieve].
17.
Altschul SF, Madden TL, Schaffer AA, et al.
Gapped BLAST and PSI-BLAST: a new generation of protein database search programs.
Nucleic Acids Res.
1997;25:3389-3402 18. Lennon G, Auffray C, Polymeropoulos M, Soares MB. The I.M.A.G.E. Consortium: an integrated molecular analysis of genomes and their expression. Genomics. 1996;33:151-152[CrossRef][Medline] [Order article via Infotrieve]. 19. Kabarowski JH, Allen PB, Wiedemann LM. A temperature sensitive p210 BCR-ABL mutant defines the primary consequences of BCR-ABL tyrosine kinase expression in growth factor dependent cells. EMBO J. 1994;13:5887-5895[Medline] [Order article via Infotrieve]. 20. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159[Medline] [Order article via Infotrieve]. 21. Cross NCP, Melo JV, Feng L, Goldman JM. An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia. 1994;8:186-189[Medline] [Order article via Infotrieve].
22.
Hochhaus A, Lin F, Reiter A, et al.
Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction.
Blood.
1996;87:1549-1555
23.
Morgenstern JP, Land H.
Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line.
Nucleic Acids Res.
1990;18:3587-3596
24.
Mahon FX, Deininger MW, Schultheis B, et al.
Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.
Blood.
2000;96:1070-1079 25. Hanenberg H, Xiao XL, Dilloo D, Hashino K, Kato I, Williams DA. Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat Med. 1996;2:876-882[CrossRef][Medline] [Order article via Infotrieve].
26.
Zhao RC, Jiang Y, Verfaillie CM.
A model of human p210bcr/ABL-mediated chronic myelogenous leukemia by transduction of primary normal human CD34(+) cells with a BCR/ABL-containing retroviral vector.
Blood.
2001;97:2406-2412
27.
Adelsman MA, McCarthy JB, Shimizu Y.
Stimulation of
28.
Deininger MW, Goldman JM, Lydon N, Melo JV.
The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells.
Blood.
1997;90:3691-3698 29. Laneuville P, Heisterkamp N, Groffen J. Expression of the chronic myelogenous leukemia-associated p210bcr/abl oncoprotein in a murine IL-3 dependent myeloid cell line. Oncogene. 1991;6:275-282[Medline] [Order article via Infotrieve].
30.
Druker BJ, Sawyers CL, Kantarjian H, et al.
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
N Engl J Med.
2001;344:1038-1042
31.
Druker BJ, Talpaz M, Resta DJ, et al.
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
N Engl J Med.
2001;344:1031-1037
32.
Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J.
Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.
Science.
2000;289:1938-1942
33.
Gaiger A, Henn T, Horth E, et al.
Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression.
Blood.
1995;86:2371-2378
34.
Ram PA, Waxman DJ.
SOCS/CIS protein inhibition of growth hormone-stimulated STAT5 signaling by multiple mechanisms.
J Biol Chem.
1999;274:35553-35561 35. Marine JC, Topham DJ, McKay C, et al. SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. Cell. 1999;98:609-616[CrossRef][Medline] [Order article via Infotrieve].
36.
Starr R, Metcalf D, Elefanty AG, et al.
Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling-1.
Proc Natl Acad Sci U S A.
1998;95:14395-14399 37. Metcalf D, Alexander WS, Elefanty AG, et al. Aberrant hematopoiesis in mice with inactivation of the gene encoding SOCS-1. Leukemia. 1999;13:926-934[CrossRef][Medline] [Order article via Infotrieve]. 38. Naka T, Fujimoto M, Kishimoto T. Negative regulation of cytokine signaling: STAT-induced STAT inhibitor. Trends Biochem Sci. 1999;24:394-398[CrossRef][Medline] [Order article via Infotrieve]. 39. Nicholson SE, Hilton DJ. The SOCS proteins: a new family of negative regulators of signal transduction. J Leukoc Biol. 1998;63:665-668[Abstract]. 40. Favre H, Benhamou A, Finidori J, Kelly PA, Edery M. Dual effects of suppressor of cytokine signaling (SOCS-2) on growth hormone signal transduction. FEBS Lett. 1999;453:63-66[CrossRef][Medline] [Order article via Infotrieve].
41.
Adams TE, Hansen JA, Starr R, Nicola NA, Hilton DJ, Billestrup N.
Growth hormone preferentially induces the rapid, transient expression of SOCS-3, a novel inhibitor of cytokine receptor signaling.
J Biol Chem.
1998;273:1285-1287 42. Yoshimura A, Ohkubo T, Kiguchi T, et al. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J. 1995;14:2816-2826[Medline] [Order article via Infotrieve].
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  J. Piessevaux, L. De Ceuninck, D. Catteeuw, F. Peelman, and J. Tavernier Elongin B/C Recruitment Regulates Substrate Binding by CIS J. Biol. Chem., August 1, 2008; 283(31): 21334 - 21346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-J. Chung, H.-S. Chi, Y.-U. Cho, C.-J. Park, E. J. Seo, K.-H. Kim, and J.-H. Lee Promyelocytic Blast Crisis of Chronic Myeloid Leukemia during Imatinib Treatment Ann. Clin. Lab. Sci., January 1, 2008; 38(3): 283 - 286. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Radich The Biology of CML Blast Crisis Hematology, January 1, 2007; 2007(1): 384 - 391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Z. Michaylira, J. G. Simmons, N. M. Ramocki, B. P. Scull, K. K. McNaughton, C. R. Fuller, and P. K. Lund Suppressor of cytokine signaling-2 limits intestinal growth and enterotrophic actions of IGF-I in vivo Am J Physiol Gastrointest Liver Physiol, September 1, 2006; 291(3): G472 - G481. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F Farabegoli, C Ceccarelli, D Santini, and M Taffurelli Suppressor of cytokine signalling 2 (SOCS-2) expression in breast carcinoma J. Clin. Pathol., October 1, 2005; 58(10): 1046 - 1050. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-F. Geay, D. Buet, Y. Zhang, A. Foudi, P. Jarrier, M. Berthebaud, A. G. Turhan, W. Vainchenker, and F. Louache p210BCR-ABL inhibits SDF-1 Chemotactic Response via Alteration of CXCR4 Signaling and Down-regulation of CXCR4 Expression Cancer Res., April 1, 2005; 65(7): 2676 - 2683. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Boverhof, E. Tam, A. S. Harney, R. B. Crawford, N. E. Kaminski, and T. R. Zacharewski 2,3,7,8-Tetrachlorodibenzo-p-dioxin Induces Suppressor of Cytokine Signaling 2 in Murine B Cells Mol. Pharmacol., December 1, 2004; 66(6): 1662 - 1670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Addya, M. A. Keller, K. Delgrosso, C. M. Ponte, R. Vadigepalli, G. E. Gonye, and S. Surrey Erythroid-induced commitment of K562 cells results in clusters of differentially expressed genes enriched for specific transcription regulatory elements Physiol Genomics, September 16, 2004; 19(1): 117 - 130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G.-J. M. van de Geijn, J. Gits, and I. P. Touw Distinct activities of suppressor of cytokine signaling (SOCS) proteins and involvement of the SOCS box in controlling G-CSF signaling J. Leukoc. Biol., July 1, 2004; 76(1): 237 - 244. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Faderl, D. Harris, Q. Van, H. M. Kantarjian, M. Talpaz, and Z. Estrov Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia Blood, July 15, 2003; 102(2): 630 - 637. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Mizuki, J. Schwable, C. Steur, C. Choudhary, S. Agrawal, B. Sargin, B. Steffen, I. Matsumura, Y. Kanakura, F. D. Bohmer, et al. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations Blood, April 15, 2003; 101(8): 3164 - 3173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Ravandi, M. Talpaz, and Z. Estrov Modulation of Cellular Signaling Pathways: Prospects for Targeted Therapy in Hematological Malignancies Clin. Cancer Res., February 1, 2003; 9(2): 535 - 550. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Greenhalgh, D. Metcalf, A. L. Thaus, J. E. Corbin, R. Uren, P. O. Morgan, L. J. Fabri, J.-G. Zhang, H. M. Martin, T. A. Willson, et al. Biological Evidence That SOCS-2 Can Act Either as an Enhancer or Suppressor of Growth Hormone Signaling J. Biol. Chem., October 18, 2002; 277(43): 40181 - 40184. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
) to 1 µM
STI571 for 10 hours. (B) Multiple-tissue Northern blot (Clontech)
probed with SOCS-2. (C) Primer design and RT-PCR
amplification of alternatively spliced variants of
SOCS-2.
